Abstract
In an attempt to identify novel therapeutic targets for diffusetype gastric cancer, we had previously compared expression profiles of 20 diffuse‐type gastric‐cancer tissues with corresponding non‐cancerous mucosae by means of a cDNA microarray consisting of 23,040 genes. Among 153 genes whose expression levels were elevated in cancers compared to non‐cancerous mucosae, we focused on a gene termed NOL8 that encodes a putative 150‐kDa protein with an RNA‐recognition motif (RRM) domain in its amino‐acid terminal region. Comparison of expression profiles between diffuse‐type and intestinal‐type gastric cancers showed that NOL8 was specifically up‐regulated in diffuse‐type cancers. Northern blot analysis revealed that NOL8 was expressed in skeletal muscle, but not expressed or hardly detectable in 22 other tissues examined. Immunocytochemical staining of NOL8 showed specific localization in the nucleolus. Subsequent protein phosphatase analysis coupled with western analysis revealed the presence of the phosphorylated form. Furthermore, transfection of short‐interfering RNA (siRNA) specific to NOL8 into three diffuse‐type gastric cancer cells, St‐4, MKN45 and TMK‐1, effectively reduced expression of this gene and induced apoptosis in these cells. These findings provide a new insight into diffuse‐type gastric carcinogenesis and may contribute to the development of new therapeutic strategies for diffuse‐type gastric cancer.
References
- 1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43. [DOI] [PubMed] [Google Scholar]
- 2. Carter SK, Comis RL. Gastric cancer: current status of treatment. J Natl Cancer Inst 1977; 58: 567–78. [DOI] [PubMed] [Google Scholar]
- 3. Molina MA, Codony‐Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti‐Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744–9. [PubMed] [Google Scholar]
- 4. O'Dwyer ME, Druker BJ. Status of bcr‐abl tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 2000; 12: 594–7. [DOI] [PubMed] [Google Scholar]
- 5. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749–54. [PubMed] [Google Scholar]
- 6. Hernandez‐Verdun D, Roussel P, Gebrane‐Younes J. Emerging concepts of nucleolar assembly. J Cell Sci 2002; 115: 2265–70. [DOI] [PubMed] [Google Scholar]
- 7. Lauren P. The two histological main types of gastric carcinoma: diffuse and so‐called intestinal‐type carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31–49. [DOI] [PubMed] [Google Scholar]
- 8. Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM, Nakamura Y. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta‐catenin/T‐cell factor complex. Cancer Res 2003; 63: 6116–20. [PubMed] [Google Scholar]
- 9. Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, Nakajima Y, Yamaoka Y, Nakamura Y. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 2003; 63: 3043–8. [PubMed] [Google Scholar]
- 10. Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, Katagiri T, Tsunoda T, Yamaoka Y, Nakamura Y. Genome‐wide analysis of gene expression in intestinal‐type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002; 62: 7012–7. [PubMed] [Google Scholar]
- 11. Olson MO, Dundr M, Szebeni A. The nucleolus: an old factory with unexpected capabilities. Trends Cell Biol 2000; 10: 189–96. [DOI] [PubMed] [Google Scholar]
- 12. Varani G, Nagai K. RNA recognition by RNP proteins during RNA processing. Annu Rev Biophys Biomol Struct 1998; 27: 407–45. [DOI] [PubMed] [Google Scholar]
- 13. Nakamura T, Imai H, Tsunashima N, Nakagawa Y. Molecular cloning and functional expression of nucleolar phospholipid hydroperoxide glutathione peroxidase in mammalian cells. Biochem Biophys Res Commun 2003; 311: 139–48. [DOI] [PubMed] [Google Scholar]
- 14. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999; 13: 1911–22. [PubMed] [Google Scholar]
- 15. Mi Y, Thomas SD, Xu X, Casson LK, Miller DM, Bates PJ. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. J Biol Chem 2003; 278: 8572–9. [DOI] [PubMed] [Google Scholar]
- 16. Grinstein E, Wernet P, Snijders PJ, Rosl F, Weinert I, Jia W, Kraft R, Schewe C, Schwabe M, Hauptmann S, Dietel M, Meijer CJ, Royer HD. Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer. J Exp Med 2002; 196: 1067–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Sekiguchi T, Todaka Y, Wang Y, Hirose E, Nakashima N, Nishimoto T. A novel human nucleolar protein, Nop132, binds to the G proteins, RRAG A/C/D. J Biol Chem 2004; 279: 8343–50. [DOI] [PubMed] [Google Scholar]